Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

281 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cytoreductive Nephrectomy Following Immune Checkpoint Inhibitor Therapy Is Safe and Facilitates Treatment-free Intervals.
Shapiro DD, Karam JA, Zemp L, Master VA, Sexton WJ, Ghasemzadeh A, Schmeusser BN, Davaro F, Peak T, Patil D, Matin S, Spiess PE, Abel EJ. Shapiro DD, et al. Among authors: karam ja. Eur Urol Open Sci. 2023 Feb 18;50:43-46. doi: 10.1016/j.euros.2023.01.016. eCollection 2023 Apr. Eur Urol Open Sci. 2023. PMID: 36861106 Free PMC article.
Reply to Alireza Ghoreifi and Hooman Djaladat's Letter to the Editor re: Daniel D. Shapiro, Jose A. Karam, Logan Zemp, et al. Cytoreductive Nephrectomy Following Immune Checkpoint Inhibitor Therapy Is Safe and Facilitates Treatment-free Intervals. Eur Urol Open Sci 2023;50:43-6.
Shapiro DD, Karam JA, Master VA, Zemp LW, Sexton WJ, Matin SF, Spiess PE, Jason Abel E. Shapiro DD, et al. Among authors: karam ja. Eur Urol. 2023 Aug;84(2):e55-e56. doi: 10.1016/j.eururo.2023.04.023. Epub 2023 May 5. Eur Urol. 2023. PMID: 37149462 No abstract available.
Phase II trial of neoadjuvant sitravatinib plus nivolumab in patients undergoing nephrectomy for locally advanced clear cell renal cell carcinoma.
Karam JA, Msaouel P, Haymaker CL, Matin SF, Campbell MT, Zurita AJ, Shah AY, Wistuba II, Marmonti E, Duose DY, Parra ER, Soto LMS, Laberiano-Fernandez C, Lozano M, Abraham A, Hallin M, Chin CD, Olson P, Der-Torossian H, Yan X, Tannir NM, Wood CG. Karam JA, et al. Nat Commun. 2023 May 10;14(1):2684. doi: 10.1038/s41467-023-38342-7. Nat Commun. 2023. PMID: 37164948 Free PMC article. Clinical Trial.
Neddylation inhibition sensitises renal medullary carcinoma tumours to platinum chemotherapy.
Shapiro DD, Zacharias NM, Tripathi DN, Karki M, Bertocchio JP, Soeung M, He R, Westerman ME, Gao J, Rao P, Lam TNA, Jonasch E, Perelli L, Cheng EH, Carugo A, Heffernan TP, Walker CL, Genovese G, Tannir NM, Karam JA, Msaouel P. Shapiro DD, et al. Among authors: karam ja. Clin Transl Med. 2023 May;13(5):e1267. doi: 10.1002/ctm2.1267. Clin Transl Med. 2023. PMID: 37226898 Free PMC article.
Re: Wesley Yip, Alireza Ghoreifi, Thomas Gerald, et al. Perioperative Complications and Oncologic Outcomes of Nephrectomy Following Immune Checkpoint Inhibitor Therapy: A Multicenter Collaborative Study. Eur Urol Oncol. Eur Urol. Onc. 2023;604-610.
Shapiro DD, Karam JA, Master VA, Sexton WJ, Matin SF, Spiess PE, Abel EJ. Shapiro DD, et al. Among authors: karam ja. Eur Urol Oncol. 2023 Dec;6(6):638-639. doi: 10.1016/j.euo.2023.05.007. Epub 2023 Jun 1. Eur Urol Oncol. 2023. PMID: 37268448 No abstract available.
Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma.
Choueiri TK, Tomczak P, Park SH, Venugopal B, Ferguson T, Symeonides SN, Hajek J, Chang YH, Lee JL, Sarwar N, Haas NB, Gurney H, Sawrycki P, Mahave M, Gross-Goupil M, Zhang T, Burke JM, Doshi G, Melichar B, Kopyltsov E, Alva A, Oudard S, Topart D, Hammers H, Kitamura H, McDermott DF, Silva A, Winquist E, Cornell J, Elfiky A, Burgents JE, Perini RF, Powles T; KEYNOTE-564 Investigators. Choueiri TK, et al. N Engl J Med. 2024 Apr 18;390(15):1359-1371. doi: 10.1056/NEJMoa2312695. N Engl J Med. 2024. PMID: 38631003 Clinical Trial.
281 results